Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.50 |
| ▸ | PGR | P06401 | 7/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650348 | 1.00 | NR3C1 (0.50) | NR3C1PGRNR3C2ALDH1A1MEN1 | |
| SCHEMBL8653902 | 0.85 | PDE5A (0.47) | NR3C1PGRNR3C2ALDH1A1POLB | |
| SCHEMBL19585644 | 0.81 | NR3C1 (0.44) | NR3C1PGRNR3C2ALDH1A1MAPK1 | |
| SCHEMBL18926938 | 0.80 | SMN1; SMN2 (0.47) | NR3C1PGRNR3C2ALDH1A1MAPK1 | |
| SCHEMBL29696630 | 0.79 | HTR6 (0.55) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL31174785 | 0.79 | NR3C1 (0.46) | NR3C1PGRNR3C2ALDH1A1MAPK1 | |
| SCHEMBL17111036 | 0.79 | HTR6 (0.55) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL4886606 | 0.78 | MEN1 (0.49) | NR3C1PGRNR3C2ALDH1A1MEN1 | |
| SCHEMBL29035965 | 0.78 | NR3C1 (0.43) | NR3C1PGRNR3C2ALDH1A1MEN1 | |
| SCHEMBL7207556 | 0.78 | NR3C1 (0.42) | NR3C1PGRNR3C2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3464292-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-109563103-B | Modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11339172-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220031690-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | HAYASHIBARA CO (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20210340154-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-10927123-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019070742-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | SIDECAR THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| EP-3464292-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109563103-A | modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2019-04-02 | — | — | CN | disclosed |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2019-01-15 | — | — | US | disclosed |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | InventisBio Co., Ltd. (CN) | 2017-12-14 | — | — | US | disclosed |
| WO-2017214002-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-7645903-B2 | immunoglobulins; affinity chromatography | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20090138208-A1 | IMMUNOGLOBULIN G BINDING POCKET | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20060014735-A1 | Use of urea variants as affinity ligands | CYTIVA BIOPROCESS R&D AB (SE) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | NR3C1 300/4885PGR 2174/4885NR3C2 61/4885 |
| US-20220031690-A1 | ANTI-NEURODEGENERATIVE DISEASE AGENT | SMN1; SMN2, NGF, NLN | NR3C1 2447/4885PGR 4178/4885NR3C2 2947/4885 |
| US-20060014735-A1 | Use of urea variants as affinity ligands | IGLV6-57, FCGR2A, FCGR3B | NR3C1 2238/4885PGR 2614/4885NR3C2 4267/4885 |
| US-20210340154-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | NR3C1 594/4885PGR 2046/4885NR3C2 67/4885 |
| US-10927123-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | NR3C1 583/4885PGR 2152/4885NR3C2 67/4885 |
| US-20170355696-A1 | PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | EGFR, WEE1, DPYD | NR3C1 2797/4885PGR 196/4885NR3C2 3197/4885 |
| US-10179784-B2 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | NR3C1 2414/4885PGR 136/4885NR3C2 3133/4885 |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | NR3C1 583/4885PGR 2152/4885NR3C2 67/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | NR3C1 277/4885PGR 2159/4885NR3C2 56/4885 |
| US-11339172-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | NR3C1 300/4885PGR 2174/4885NR3C2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.